Microdosing GLP-1s: What the Science Says
Sub-therapeutic GLP-1 dosing has become a popular maintenance and longevity strategy. Here's where the evidence supports it and where it gets ahead of the data.
Microdosing — using GLP-1 medications at doses well below the labeled therapeutic range — has moved from niche to mainstream. The rationale is sound; the evidence is partial.
What microdosing means
In practice, microdosing typically refers to 0.125–0.25 mg of semaglutide weekly, or 1.0–2.5 mg of tirzepatide weekly. These doses are roughly one-tenth to one-quarter of the standard weight-loss range.
The metabolic case
Even at sub-therapeutic doses, GLP-1 agonists exert measurable effects on appetite, gastric emptying, and insulin sensitivity. For weight maintenance after a successful loss phase, this can be sufficient to prevent regain without the cost or side effects of full doses.
The longevity case
A separate argument extends GLP-1 use to metabolically healthy patients seeking improved insulin sensitivity, reduced inflammation, and possibly cardiovascular benefit. The mechanistic case is reasonable; randomized data in non-obese populations is limited.
Where the evidence ends
We have strong randomized data for therapeutic-dose GLP-1s in obesity and type 2 diabetes. We have observational data and physiology to support maintenance dosing. We do not yet have large randomized trials evaluating sub-therapeutic dosing as primary therapy in metabolically healthy adults.
Practical guidance
Microdosing is reasonable as a maintenance strategy after standard weight-loss therapy and as a tool for patients with insulin resistance or pre-diabetes who do not yet meet BMI criteria for standard dosing. It should always be physician-supervised, with periodic labs and a clear clinical rationale documented.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metab. 2018;27:740-756.— Cell Metabolism, 2018.
- 2.Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.— New England Journal of Medicine, 2023.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
